App Note: How Merck creates developability profiles for mAbs

Monoclonal antibodies

Download this new Application Note to discover how the Protein Sciences group at Merck & Co. builds developability profiles for their monoclonal antibody variants.

Get an in-depth explanation of the experiments they set up to obtain parameters that help them decide which candidates have the best potential to reach the market, and how they validated that the data they obtained to do this work matched up with previous profiles.

You’ll learn about:

  • Why it was important for Merck to build developability profiles from biophysical stability attributes of their candidates
  • Which parameters they measured to create these profiles
  • Why a combinatorial approach was valuable to their workflow
  • How they validated that the addition of DLS-derived parameters did not compromise their previous nanoDSF-derived data

Download now.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free